These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

722 related articles for article (PubMed ID: 29706008)

  • 21. Efficacy and safety of adalimumab across subgroups of patients with moderate to severe psoriasis.
    Menter A; Gordon KB; Leonardi CL; Gu Y; Goldblum OM
    J Am Acad Dermatol; 2010 Sep; 63(3):448-56. PubMed ID: 20605254
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Guselkumab: A Review in Moderate to Severe Plaque Psoriasis.
    Al-Salama ZT; Scott LJ
    Am J Clin Dermatol; 2018 Dec; 19(6):907-918. PubMed ID: 30467781
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Guselkumab versus secukinumab for the treatment of moderate-to-severe psoriasis (ECLIPSE): results from a phase 3, randomised controlled trial.
    Reich K; Armstrong AW; Langley RG; Flavin S; Randazzo B; Li S; Hsu MC; Branigan P; Blauvelt A
    Lancet; 2019 Sep; 394(10201):831-839. PubMed ID: 31402114
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Ustekinumab significantly improves symptoms of anxiety, depression, and skin-related quality of life in patients with moderate-to-severe psoriasis: Results from a randomized, double-blind, placebo-controlled phase III trial.
    Langley RG; Feldman SR; Han C; Schenkel B; Szapary P; Hsu MC; Ortonne JP; Gordon KB; Kimball AB
    J Am Acad Dermatol; 2010 Sep; 63(3):457-65. PubMed ID: 20462664
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effect of Risankizumab on Patient-Reported Outcomes in Moderate to Severe Psoriasis: The UltIMMa-1 and UltIMMa-2 Randomized Clinical Trials.
    Augustin M; Lambert J; Zema C; Thompson EHZ; Yang M; Wu EQ; Garcia-Horton V; Geng Z; Valdes JM; Joshi A; Gordon KB
    JAMA Dermatol; 2020 Dec; 156(12):1344-1353. PubMed ID: 33052382
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Safety in moderate-to-severe plaque psoriasis patients with latent tuberculosis treated with guselkumab and anti-tuberculosis treatments concomitantly: results from pooled phase 3 VOYAGE 1 & VOYAGE 2 trials.
    Puig L; Tsai TF; Bhutani T; Uy J; Ramachandran P; Song M; You Y; Gooderham M; Lebwohl M
    J Eur Acad Dermatol Venereol; 2020 Aug; 34(8):1744-1749. PubMed ID: 32289190
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Safety and efficacy of guselkumab in Japanese patients with moderate-to-severe plaque psoriasis: a randomized, placebo-controlled, ascending-dose study.
    Nemoto O; Hirose K; Shibata S; Li K; Kubo H
    Br J Dermatol; 2018 Mar; 178(3):689-696. PubMed ID: 29222947
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Efficacy and Safety of Guselkumab, an Anti-interleukin 23 Monoclonal Antibody, for Palmoplantar Pustulosis: A Randomized Clinical Trial.
    Terui T; Kobayashi S; Okubo Y; Murakami M; Hirose K; Kubo H
    JAMA Dermatol; 2018 Mar; 154(3):309-316. PubMed ID: 29417135
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The effect of adalimumab on reducing depression symptoms in patients with moderate to severe psoriasis: a randomized clinical trial.
    Menter A; Augustin M; Signorovitch J; Yu AP; Wu EQ; Gupta SR; Bao Y; Mulani P
    J Am Acad Dermatol; 2010 May; 62(5):812-8. PubMed ID: 20219265
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Adalimumab for nail psoriasis: Efficacy and safety from the first 26 weeks of a phase 3, randomized, placebo-controlled trial.
    Elewski BE; Okun MM; Papp K; Baker CS; Crowley JJ; Guillet G; Sundaram M; Poulin Y; Gu Y; Geng Z; Williams DA; Rich PA
    J Am Acad Dermatol; 2018 Jan; 78(1):90-99.e1. PubMed ID: 28993005
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Guselkumab (an IL-23-specific mAb) demonstrates clinical and molecular response in patients with moderate-to-severe psoriasis.
    Sofen H; Smith S; Matheson RT; Leonardi CL; Calderon C; Brodmerkel C; Li K; Campbell K; Marciniak SJ; Wasfi Y; Wang Y; Szapary P; Krueger JG
    J Allergy Clin Immunol; 2014 Apr; 133(4):1032-40. PubMed ID: 24679469
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Nail psoriasis dynamics during biologic treatment and withdrawal in patients with psoriasis who may be at high risk of developing psoriatic arthritis: a post hoc analysis of the VOYAGE 2 randomized trial.
    Tillett W; Egeberg A; Sonkoly E; Gorecki P; Tjärnlund A; Buyze J; Wegner S; McGonagle D
    Arthritis Res Ther; 2023 Sep; 25(1):169. PubMed ID: 37715294
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Efficacy and safety of guselkumab in patients with psoriasis who have an inadequate response to ustekinumab: results of the randomized, double-blind, phase III NAVIGATE trial.
    Langley RG; Tsai TF; Flavin S; Song M; Randazzo B; Wasfi Y; Jiang J; Li S; Puig L
    Br J Dermatol; 2018 Jan; 178(1):114-123. PubMed ID: 28635018
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Consistent safety profile with up to 5 years of continuous treatment with guselkumab: Pooled analyses from the phase 3 VOYAGE 1 and VOYAGE 2 trials of patients with moderate-to-severe psoriasis.
    Blauvelt A; Tsai TF; Langley RG; Miller M; Shen YK; You Y; Yang YW; Papp KA; Puig L
    J Am Acad Dermatol; 2022 Apr; 86(4):827-834. PubMed ID: 34798201
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Safety of guselkumab treatment for up to 5 years in patients with moderate-to-severe psoriasis: pooled analyses across seven clinical trials with more than 8600 patient-years of exposure.
    Lebwohl MG; Merola JF; Rowland K; Miller M; Yang YW; Yu J; You Y; Chan D; Thaçi D; Langley RG
    Br J Dermatol; 2023 Jul; 189(1):42-52. PubMed ID: 37022762
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Work/study productivity gain and associated indirect cost savings with guselkumab compared with adalimumab in moderate-to-severe psoriasis: results from the VOYAGE 1 study.
    Li N; Teeple A; Muser E; You Y; Song M; Armstrong AW
    J Dermatolog Treat; 2022 Feb; 33(1):278-283. PubMed ID: 32233940
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Super-response to guselkumab treatment in patients with moderate-to-severe psoriasis: age, body weight, baseline Psoriasis Area and Severity Index, and baseline Investigator's Global Assessment scores predict complete skin clearance.
    Reich K; Gordon KB; Strober B; Langley RG; Miller M; Yang YW; Shen YK; You Y; Zhu Y; Foley P; Blauvelt A
    J Eur Acad Dermatol Venereol; 2022 Dec; 36(12):2393-2400. PubMed ID: 35920762
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Direct and Indirect Effect of Guselkumab on Anxiety, Depression, and Quality of Life in Patients with Moderate-to-Severe Plaque Psoriasis: A Mediation Analysis.
    Armstrong AW; Foley P; Liu Y; Miller M; Teneralli RE; Bewley A; Gordon KB; Papp KA; Han C
    Dermatol Ther (Heidelb); 2024 Sep; 14(9):2577-2589. PubMed ID: 39177870
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Adalimumab improves health-related quality of life in patients with moderate to severe plaque psoriasis compared with the United States general population norms: results from a randomized, controlled Phase III study.
    Revicki DA; Menter A; Feldman S; Kimel M; Harnam N; Willian MK
    Health Qual Life Outcomes; 2008 Oct; 6():75. PubMed ID: 18831744
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Consistent responses with guselkumab treatment in Asian and non-Asian patients with psoriasis: An analysis from VOYAGE 1 and VOYAGE 2.
    Reich K; Song M; Li S; Jiang J; Youn SW; Tsai TF; Choe YB; Huang YH; Gordon KB
    J Dermatol; 2019 Dec; 46(12):1141-1152. PubMed ID: 31631377
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 37.